Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity.
The human myeloid leukemias are a diverse group of disorders characterized by massive clonal expansion of myeloid cells showing variable degrees of differentiation block. Leukemic dendritic cells were generated in culture from chronic myelogenous leukemia (CML). These were used to stimulate autologous T cells to develop leukemia-specific cytotoxicity. Available data suggest that the cells responsible for the cytolytic activity are at least in part CD8+ and HLA restricted in their function. Additional data suggest that some anti-CML cellular activity may be Fas mediated. T-cell receptor studies provide evidence for an oligoclonal response implying a recognition of a limited number of antigens. We have used culture techniques similar to those used for CML to study the ability of AML cells to differentiate toward dendritic cells. Four of five patients have shown acute leukemia-derived dendritic cells. This work offers an avenue for the development of novel strategies for the control of human myeloid leukemias.
Choudhury
A
A
Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
Toubert
A
A
Sutaria
S
S
Charron
D
D
Champlin
R E
RE
Claxton
D F
DF
D003601:Cytotoxicity Tests, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000628:therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000276:immunology; D010677:Philadelphia Chromosome; D011948:Receptors, Antigen, T-Cell / Q000276:immunology
D011948:Receptors, Antigen, T-Cell